Alpha-glucosidase Inhibitors Market size is estimated at USD 3.4 billion in 2024 and is predicted to exceed USD 5.4 billion by the end of 2037, growing at over 3.7% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of alpha-glucosidase inhibitors is assessed at USD 3.5 billion.
One of the major factors boosting the alpha-glucosidase inhibitors market is the increasing prevalence of diabetes across the world. For instance, according to a 2023 published report by the Institute for Health Metrics and Evaluation (IHME), , states that more than half a billion people are living with diabetes around the globe. The worldwide prevalence rate of diabetes is 6.1%, whereas North America and the Middle East hold 9.3% and is predicted to reach 16.8% by 2050. Furthermore, based on demographics, people 65 and older age are capturing more than 20% of the diabetes prevalence rate. The rising risk of diabetes drives demand for effective glucose management therapies and is generating profitable opportunities for anti-diabetic drug producers. Moreover, the key market players are investing heavily in research and development activities to introduce advanced and effective solutions such as alpha-glucosidase inhibitors.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.7% |
|
Base Year Market Size (2024) |
USD 3.4 billion |
|
Forecast Year Market Size (2037) |
USD 5.4 billion |
|
Regional Scope |
|
Indication (Type 2 Diabetes Mellitus, Pre-diabetes)
Type 2 diabetes mellitus segment is estimated to account for more than 89.5% alpha-glucosidase inhibitors market share by the end of 2037. The increasing prevalence of type 2 diabetes mellitus globally creates a substantial population in need of effective management solutions. For instance, the prevalence of type 2 diabetes mellitus among older adults accounted for 96% in 2021. As per the analysis by the World Health Organization (WHO), around 95% of people living with diabetes have type 2 diabetes. Alpha-glucosidase inhibitors specifically target postprandial blood sugar levels, making them valuable for managing the unique challenges faced by type 2 diabetes patients.
Drug Type (Acarbose, Miglitol, Voglibose, Combination Drugs)
The acarbose drug type segment in alpha-glucosidase inhibitors market is foreseen to hold a dominant revenue share through 2037 owing to its effectiveness in the treatment of diabetes. Acarbose has a proven track record in effectively managing postprandial blood glucose levels, making it a trusted choice among healthcare providers. The drug is often included in diabetes management guidelines, which supports its continued use in clinical practice and drives demand.
Acarbose has strong brand recognition and is marketed under various names, such as Glucobay in Europe and Asia, Precose in the U.S., and Prandase in Canada. Moreover, Acarbose is frequently used in combination with other antidiabetic medications, further enhancing its effectiveness and broadening its use among patients.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type
|
|
|
Indication |
|
|
Type |
|
|
Distribution Channel |
|
North America Market Forecast
North America in alpha-glucosidase inhibitors market is estimated to account for more than 40.7% revenue share by the end of 2037, owing to the high prevalence of type 2 diabetes and advancements in drug production. The region has a strong presence of antidiabetic drug producers and advanced research and treatment organizations, which is positively influencing the sales of alpha-glucosidase inhibitors.
The U.S. market for alpha-glucosidase inhibitors was valued at USD 1.2 billion in 2023 and is expected to expand at a steady CAGR during the forecasted period. According to a 2024 report published by the Centers for Disease Control and Prevention (CDC) states that more than 38 million individuals have diabetes with type 2 diabetes accounting for 90% to 95% of the total. Although type 2 diabetes primarily affects those 45 years of age and older, it is also increasingly occurring in children, teenagers, and young adults.
Improved patient education about diabetes management options and access to healthcare services in the country enhances the likelihood of prescribing alpha-glucosidase inhibitors.
Canada is witnessing a rising prevalence of diabetes that is augmenting the need for advanced therapeutics such as alpha-glucosidase inhibitors. For instance, according to Diabetes Canada, 30% of the individuals in the country are living with diabetes. Moreover, rise in clinical research in Canada is crucial for validating and enhancing the role of alpha-glucosidase inhibitors in diabetes management, ultimately driving market growth and adoption.
APAC Market Statistics
Asia Pacific alpha-glucosidase inhibitors market is expected to observe over 4% growth between 2025 and 2037, owing to the increased healthcare expenditure. Several governments in the region are highly investing in advancing their healthcare infrastructure, which is set to drive the sales of antidiabetic drugs including alpha-glucosidase inhibitors. India, Japan, South Korea, and China are some of the top markets for alpha-glucosidase inhibitors in the region.
India is foreseen to witness high sales of alpha-glucosidase inhibitors owing to the growing cases of diabetes and rising government initiatives. India is home to the world's second highest number of diabetic patients. According to the National Center for Disease Control, Government of India, the country is projected to have 1.09 billion diabetes cases by 2035. Non-communicable diseases cause 9.8 million fatalities in the country, with diabetes accounting for 2% of total deaths each year.
Additionally, government health programs such as National Diabetes Control Program aims at managing diabetes and promoting preventive healthcare thus, contributing to the increased use of diabetes medications such as alpha-glucosidase inhibitors.
The key players in the alpha-glucosidase inhibitors market are employing strategies such as the introduction of innovative drug solutions, strategic partnerships, mergers & acquisitions, and regional expansions. Leading companies are collaborating with research organizations and other players to develop advanced alpha-glucosidase inhibitors formulations and earn high profits. They are also acquiring other companies to expand their portfolio and reach a wider consumer base. Furthermore, regional expansion strategies are aiding them to tap into emerging marketplaces.
Some of the key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?